TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro-Reference-Cited by-同舟云学术

TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro

Published:2005-08 Issue:8 Volume:49 Page:3483-3485
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tremblay Cécile L.¹²,Giguel Françoise¹,Guan Yongbiao³,Chou Ting-Chao³,Takashima Katsunori⁴,Hirsch Martin S.¹

Affiliation:

1. Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Cambridge, Massachusetts

2. Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada

3. Memorial Sloan-Kettering Cancer Center, New York, New York

4. Takeda Pharmaceutical Company, Ltd., Osaka, Japan

Abstract

ABSTRACT TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various antiretrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.8.3483-3485.2005

Reference17 articles.

1. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul.22:27-55.

2. Chou, T. C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T. C. Chou and D. C. Rideout, (ed.) Synergism and antagonism in chemotherapy. Academic Press, Inc., San Diego, Calif.

3. Doms, R. W. 2004. Viral entry denied. N. Engl. J. Med.351:743-744.

4. Doms, R. W., and S. C. Peiper. 1997. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology235:179-190.

5. Havlir, D. V., C. Tierney, G. H. Friedland, R. B. Pollard, L. Smeaton, J.-P. Sommadossi, L. Fox, H. Kessler, K. H. Fife, and D. D. Richman. 2000. In vivo antagonism with zidovudine plus stavudine combination therapy. J. Infect. Dis.182:321-325.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses;European Journal of Medicinal Chemistry;2024-02

2. A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region;Journal of Medicinal Chemistry;2021-07-15

3. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210;AIDS Research and Human Retroviruses;2019-08

4. Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus–Cell Interface;Journal of Medicinal Chemistry;2018-05-16

5. Medicinal Chemistry of Small Molecule CCR5 Antagonists for Blocking HIV-1 Entry: A Review of Structural Evolution;Current Topics in Medicinal Chemistry;2014-09